

Borland Scott  
Form 3  
August 04, 2011

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |                                      |  |  |
|---|---------|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person * |         | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol |  |
| Â Borland Scott                           |         | (Month/Day/Year)                     | MAP Pharmaceuticals, Inc. [MAPP]                   |  |
| (Last)                                    | (First) | (Middle)                             | 07/21/2011   |  |
| 2400 BAYSHORE PARKWAY<br>SUITE 200        |         |                                      | 4. Relationship of Reporting Person(s) to Issuer   | 5. If Amendment, Date Original Filed(Month/Day/Year)                   |
| (Street)                                  |         |                                      | (Check all applicable)                             |  |
| MOUNTAIN VIEW,Â CAÂ 94043                 |         |                                      | <input type="checkbox"/> Director                  | <input type="checkbox"/> 10% Owner                                     |
| (City)                                    | (State) | (Zip)                                | <input checked="" type="checkbox"/> Officer        | <input type="checkbox"/> Other   |
|   |         |                                      | (give title below)                                 | (specify below)  |
|   |         |                                      | SVP, Neurology Franchise                           | 6. Individual or Joint/Group Filing(Check Applicable Line)             |
|   |         |                                      |  | <input checked="" type="checkbox"/> Form filed by One Reporting Person |
|   |         |                                      |  | <input type="checkbox"/> Form filed by More than One Reporting Person  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock                    | 981   | D  | Â   |
| Common Stock                    | 321   | I  | See Footnote <sup>(1)</sup>                           |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of | 5. Ownership Form of Derivative | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---|------------------------------------|---------------------------------|---|
|--|--|---|------------------------------------|---------------------------------|---|

Edgar Filing: Borland Scott - Form 3

|                             | Date<br>Exercisable | Expiration<br>Date | Title        | Amount or<br>Number of<br>Shares | Derivative<br>Security | Security:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) |                         |
|-----------------------------|---------------------|--------------------|--------------|----------------------------------|------------------------|---|-------------------------|
| Stock Option (Right to Buy) | Â <u>(2)</u>        | 03/05/2017         | Common Stock | 1,648                            | \$ 3.363               | D   | Â                       |
| Stock Option (Right to Buy) | Â <u>(2)</u>        | 05/01/2017         | Common Stock | 1,589                            | \$ 6.3897              | D   | Â                       |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 01/21/2018         | Common Stock | 10,000                           | \$ 13.12               | D   | Â                       |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 02/10/2019         | Common Stock | 51,500                           | \$ 10.37               | D   | Â                       |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 02/01/2020         | Common Stock | 35,000                           | \$ 16.19               | D   | Â                       |
| Restricted Stock Unit       | Â <u>(4)</u>        | 02/01/2020         | Common Stock | 10,000                           | \$ <u>(5)</u>          | D   | Â                       |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 01/25/2021         | Common Stock | 21,000                           | \$ 16.15               | D   | Â                       |
| Restricted Stock Unit       | Â <u>(6)</u>        | 01/25/2021         | Common Stock | 7,000                            | \$ <u>(5)</u>          | D   | Â                       |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 06/06/2021         | Common Stock | 13,750                           | \$ 15.38               | D   | Â                       |
| Restricted Stock Unit       | Â <u>(7)</u>        | 06/06/2021         | Common Stock | 4,500                            | \$ <u>(5)</u>          | D   | Â                       |
| Stock Option (Right to Buy) | Â <u>(2)</u>        | 03/06/2017         | Common Stock | 248                              | \$ 3.363               | I   | See Footnote <u>(1)</u> |
| Stock Option (Right to Buy) | Â <u>(2)</u>        | 05/01/2017         | Common Stock | 4,237                            | \$ 6.3897              | I   | See Footnote <u>(1)</u> |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 01/21/2018         | Common Stock | 2,500                            | \$ 13.12               | I   | See Footnote <u>(1)</u> |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 02/10/2019         | Common Stock | 5,000                            | \$ 10.37               | I   | See Footnote <u>(1)</u> |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 02/01/2020         | Common Stock | 4,375                            | \$ 16.19               | I   | See Footnote <u>(1)</u> |
| Stock Option (Right to Buy) | Â <u>(3)</u>        | 01/25/2021         | Common Stock | 1,800                            | \$ 16.15               | I   | See Footnote <u>(1)</u> |
| Restricted Stock Unit       | Â <u>(6)</u>        | 01/25/2021         | Common Stock | 600                              | \$ <u>(5)</u>          | I   | See Footnote <u>(1)</u> |

# Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                            |       |
|---|---------------|-----------|----------------------------|-------|
|   | Director      | 10% Owner | Officer                    | Other |
| Borland Scott<br>2400 BAYSHORE PARKWAY SUITE 200<br>MOUNTAIN VIEW, CA 94043 | Å             | Å         | Å SVP, Neurology Franchise | Å     |

## Signatures

/s/ Scott Borland                      08/04/2011

\*\*Signature of  
Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares held by the spouse of the reporting person. The reporting person disclaims beneficial beneficiary ownership of the shares except to the extent of his pecuniary interest therein.
- (2) Fully exercisable.
- (3) The option is exercisable as it vests: 25% of the total number of option shares vests and becomes exercisable on the first anniversary of the vesting commencement date. Thereafter, 1/48th of the total number of option shares becomes exercisable cumulatively on each monthly anniversary for 36 months so that the entire number of option shares becomes fully vested.
- (4) Vesting of the RSU award is performance-based.
- (5) Each RSU represents a contingent right to receive one share of MAP common stock.
- (6) 25% of the total number of RSUs vests and becomes payable on each anniversary of January 26, 2011, such that all RSUs subject to this award shall be fully vested on January 26, 2015.
- (7) 25% of the total number of RSUs vests and becomes payable on each anniversary of June 07, 2011, such that all RSUs subject to this award shall be fully vested on June 07, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.